1. Lipopolysaccharide enhances interferon-γ-induced nitric oxide (NO) production in murine vascular endothelial cells via augmentation of interferon regulatory factor-1 activation
- Author
-
Jargalsaikhan Dagvadorj, Ferdaus Hassan, Naoki Koide, Shamima Islam, Yoshikazu Naiki, Gantsetseg Tumurkhuu, Tomoaki Yoshida, Isamu Mori, Takashi Yokochi, and Mya Mya Mu
- Subjects
Lipopolysaccharides ,0301 basic medicine ,Endothelium ,Lipopolysaccharide ,030106 microbiology ,Immunology ,Nitric Oxide Synthase Type II ,Nitric Oxide ,Microbiology ,Cell Line ,Nitric oxide ,Interferon-gamma ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Genes, Reporter ,Interferon ,medicine ,Animals ,RNA, Messenger ,Luciferases ,Molecular Biology ,Aorta ,Nitrites ,Endothelial Cells ,Cell Biology ,Immunohistochemistry ,Recombinant Proteins ,Cell biology ,Endothelial stem cell ,Infectious Diseases ,medicine.anatomical_structure ,IRF1 ,chemistry ,Cell culture ,Endothelium, Vascular ,Interferon Regulatory Factor-1 ,030215 immunology ,Interferon regulatory factors ,medicine.drug - Abstract
Lipopolysaccharide (LPS) enhances the production of nitric oxide (NO) in interferon (IFN)-gamma-stimulated vascular endothelial cells. We studied the mechanism by which LPS enhances IFN-gamma-induced NO production by using the murine vascular endothelial cell line, END-D. LPS enhanced IFN-gamma-induced NO production via augmented expression of inducible type NO synthase (iNOS) mRNA. LPS significantly augmented the activation of interferon regulatory factor (IRF)-1 in IFN-gamma-stimulated END-D cells, although it did not affect the activation of either MyD88-dependent nuclear factor (NF)-kappaB or MyD88-independent IRF-3. SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK), prevented the nuclear translocation of IRF-1 in LPS and IFN-gamma-stimulated END-D cells, and inhibited the iNOS expression and NO production in those cells. Therefore, it is proposed that LPS enhanced NO production in IFN-gamma-stimulated END-D cells via augmenting p38 MAPKmediated IRF-1 activation.
- Published
- 2007
- Full Text
- View/download PDF